Sun Pharmaceutical Industries is planning to raise up to Rs 12,000 crore through convertible debentures or a qualified institutional placement (QIP). In this regard, the company is seeking shareholder approval.
The company will use the raised fund for expansion and acquisitions. The company would allow it to strengthen its financial resources and net worth. Following the merger with Ranbaxy Pharmaceuticals, the company has been restructuring its business and rationalizing its manufacturing footprint.
Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. The company provides high quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1648.00 |
| Dr. Reddys Lab | 1323.20 |
| Cipla | 1289.70 |
| Zydus Lifesciences | 937.70 |
| Lupin | 2330.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: